FDA approves Icotyde for moderate-to-severe plaque psoriasis

Johnson & Johnson has secured a new FDA approval in immunodermatology: Icotyde, the brand name for icotrokinra, is now approved in the U.S. for moderate-to-severe plaque psoriasis in adults and in patients age 12 and older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy. Announced March 18, 2026, the decision gives Johnson & Johnson what it describes as the first approved targeted oral peptide to precisely block the IL-23 receptor, positioning the drug as a new oral entrant in a category where convenience, safety, and durable efficacy all matter. (investor.jnj.com)

The approval builds on a multiyear development effort around icotrokinra, which Johnson & Johnson and Protagonist Therapeutics jointly discovered under their IL-23 receptor collaboration. By mid-2025, Protagonist had disclosed that an NDA approval in any indication would trigger a $50 million milestone payment from Johnson & Johnson, underscoring the commercial significance of the psoriasis filing and approval. The program has also broadened beyond psoriasis, with positive phase 2b ulcerative colitis data reported in 2025 and additional inflammatory bowel disease studies planned, suggesting Johnson & Johnson sees icotrokinra as a platform asset rather than a single-indication product. (sec.gov)

On the label, Icotyde is a 200 mg oral tablet taken once daily upon waking with water, at least 30 minutes before food. The prescribing information also includes an alternative water-dispersion method for patients who have difficulty swallowing tablets. FDA labeling notes no listed contraindications, but it does call for attention to clinically important active infections, consideration of tuberculosis evaluation before treatment, and completion of age-appropriate immunizations before starting therapy. (fda.report)

The clinical case for approval came from four phase 3 psoriasis studies pooled for safety, covering 2,367 adults and adolescents who received icotrokinra, with 648 exposed for at least one year. In those pooled trials, the most common adverse reactions occurring more often than placebo were headache, nausea, cough, fungal infection, and fatigue. Johnson & Johnson has also continued to release longer-term efficacy data: on March 28, 2026, the company reported 52-week results showing increasing rates of complete skin clearance over time in the ICONIC-ADVANCE studies, and said nearly 60% of adolescents treated in ICONIC-LEAD achieved completely clear skin at one year. (fda.report)

Industry messaging around the launch has focused heavily on differentiation from existing oral therapies. In September 2025, Johnson & Johnson reported head-to-head phase 3 data suggesting icotrokinra outperformed deucravacitinib on complete skin clearance endpoints, and it has also launched the ICONIC-ASCEND study comparing icotrokinra with ustekinumab. Company-linked expert commentary has been notably bullish: Linda Stein Gold of Henry Ford Health said the head-to-head data showed superior complete skin clearance rates versus deucravacitinib, while Jennifer Soung of Southern California Dermatology said the one-year data suggest sustained clearance with a favorable safety profile in a once-daily pill. Both physicians were identified by Johnson & Johnson as study investigators and paid consultants, an important context point for readers weighing those remarks. (innovativemedicine.jnj.com)

Why it matters: For veterinary professionals, this isn’t a veterinary approval, but it is still relevant. Human dermatology and immunology often provide an early read on where targeted inflammatory therapeutics are heading, especially around cytokine signaling, oral peptide delivery, long-term safety framing, and patient adherence. A once-daily oral IL-23-pathway drug that gains regulatory traction could influence translational thinking in companion-animal dermatology and immune-mediated disease research, while also shaping pet parent expectations as they hear more about highly targeted, easier-to-administer therapies in human medicine. (investor.jnj.com)

There’s also a business and competitive angle worth watching. Psoriasis remains crowded, but oral therapies still occupy an important niche for patients and clinicians trying to avoid injections. If Icotyde’s real-world uptake matches Johnson & Johnson’s positioning, it could put pressure on other oral immunology programs, including Takeda’s phase 3 zasocitinib program in plaque psoriasis, which the company highlighted at AAD 2026. That makes Icotyde’s launch more than a single approval story; it may be an early signal of a new competitive phase in oral targeted immunology. (innovativemedicine.jnj.com)

What to watch: Near term, watch for payer coverage, formulary access, and any early launch disclosures from Johnson & Johnson, along with further readouts from ICONIC-ASCEND and any regulatory moves in ulcerative colitis or other follow-on indications. Protagonist’s milestone structure also means future approvals could have clear financial implications beyond the clinical story. (sec.gov)